Journal of Diagnostics Concepts & Practice >

2021 , Vol. 20 >Issue 03: 284 - 289

DOI: https://doi.org/10.16150/j.1671-2870.2021.03.010

Original articles

Risk factors of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes

Expand
  • Department of General Surgery, Chaoyang Central Hospital, Liaoning Chaoyang 122000, China

Received date: 2019-10-20

  Online published: 2022-06-28

Fold

Abstract

Objective: To analyze the risk factors for non-sentinel lymph node (nSLN) metastasis in patients with sentinel lymph node-positive breast cancer. Methods: A retrospective analysis was performed on 154 breast cancer patients admitted to our hospital with SLN positive and axillary lymph node dissection. According to weather nSLN metastasis occurred or not, patients were divided into 2 groups : nSLN metastasis negative (nSLN-group,81 cases)and nSLN metastasis positive(nSLN+group,73cases).Univariate and multivariate Logistic regression were used to analyze risk factors for nSLN metastasis. Results: The rate of non-sentinel lymph node metastasis in patients was 47.4% (73/154). Univariate analysis showed that primary tumor T staging, vascular invasion, number of SLN positive, human epidermal growth factor receptor-2, neutrophils/lymphocytes ratio (NLR), and platelets/lymphocytes ratio (PLR) were associated with non-sentinel lymph node metastasis. Further multivariate Logistic regression analysis showed that primary tumor T stage (P=0.040, OR=2.235), NLR (P=0.021, OR=2.073), and number of SLN metastasis (P=0.008, OR=3.763) were independent risk factors for nSLN metastasis. Conclusions: High T stage of primary tumor, NLR>2.82, and the number of SLN>2 are independent risk factors for nSLN metastasis in SLN-metastasis. For patients with risk factors above mentioned,application of axillary lymph node dissection are more important in them.

Key words： Breast cancer; Sentinel lymph node biopsy; Nonsentinel lymph node; Axillary lymph node dissection

Cite this article

HOU Xiaosa, YANG Zhenjiang . Risk factors of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes[J]. Journal of Diagnostics Concepts & Practice, 2021 , 20(03) : 284 -289 . DOI: 10.16150/j.1671-2870.2021.03.010

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer[J]. Ann Surg, 1994, 220(3):391-398.
[3] Abass MO, Gismalla MDA, Alsheikh AA, et al. Axillary lymph node dissection for breast cancer: efficacy and complication in developing countries[J]. J Glob Oncol, 2018, 4:1-8.
[4] Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393.
[5] Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2):93-99.
[6] 李雪迎. 诊断能力评价的统计学方法——准确度与约登指数[J]. 中国介入心脏病学杂志, 2011, 19(4):213.
[7] Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6):569-575.
[8] Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12):1303-1310.
[9] Tseng HS, Chen LS, Kuo SJ, et al. Tumor characteristics of breast cancer in predicting axillary lymph node metastasis[J]. Med Sci Monit, 2014, 20:1155-1161.
[10] Gruber I, Henzel M, Schönfisch B, et al. Prediction of non-sentinel lymph node metastases after positive sentinel lymph nodes using nomograms[J]. Anticancer Res, 2018, 38(7):4047-4056.
[11] 郑丽华, 刘峰, 张硕, 等. 中国人群非前哨淋巴结转移预测模型研究[J]. 中华肿瘤防治杂志, 2020, 27(1):63-70.
[12] Houvenaeghel G, Lambaudie E, Classe JM, et al. Lymph node positivity in different early breast carcinoma phenotypes: a predictive model[J]. BMC Cancer, 2019, 19(1):45.
[13] 孟垒, 肖琪, 李钊, 等. 前哨淋巴结1-2枚阳性乳腺癌患者非前哨淋巴结转移的影响因素[J]. 第三军医大学学报, 2020, 42(11):1130-1135.
[14] Kolb R, Kluz P, Tan ZW, et al. Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4[J]. Oncogene, 2019, 38(13):2351-2363.
[15] Bodogai M, Moritoh K, Lee-Chang C, et al. Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associa-ted B cells[J]. Cancer Res, 2015, 75(17):3456-3465.
[16] Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents[J]. Blood, 2018, 131(16):1777-1789.
[17] 朱振成, 罗昆仑, 谢伟选, 等. 术前/术后中性粒细胞-淋巴细胞比值与格拉斯哥预后评分对胆囊癌预后的预测价值[J]. 中国普通外科杂志, 2020, 29(8):947-957.
[18] Dertli R, Asil M, Biyik M, et al. Can hematological inflammatory parameters predict mortality in hepatocellular carcinoma?[J]. J Gastrointest Cancer, 2021, 52(2):666-675.
[19] 迟涛, 尹明明, 胡知齐. 术前外周血多指标联合检测分析在乳腺癌诊断中应用价值[J]. 中华肿瘤防治杂志, 2020, 27(9):730-734,739.
[20] Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio(NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: a meta-analysis[J]. Medicine (Baltimore), 2018, 97(49):e13340.
[21] Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, et al. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer[J]. PLoS One, 2018, 13(11):e0207224.
[22] 薛婷. NLR、PLR、SII、ABI对乳腺癌非前哨淋巴结转移的预测分析[D]. 吉林大学, 2020.
[23] Ishizuka Y, Horimoto Y, Nakamura M, et al. Predictive factors for non-sentinel nodal metastasis in patients with sentinel lymph node-positive breast cancer[J]. Anticancer Res, 2020, 40(8):4405-4412.
[24] Sylman JL, Boyce HB, Mitrugno A, et al. A Temporal examination of platelet counts as a predictor of prognosis in lung, prostate, and colon cancer patients[J]. Sci Rep, 2018, 8(1):6564.
[25] Lale A, Yur M, Özgül H, et al. Predictors of non-sentinel lymph node metastasis in clinical early stage (cT1-2N0) breast cancer patients with 1-2 metastatic sentinel lymph nodes[J]. Asian J Surg, 2020, 43(4):538-549.
Options
Outlines

/

〈 〉